Capital at risk

Investment strategy

Health Innovation

Healthcare is undergoing monumental change. Perhaps more than any other sector, it offers extreme payoffs for those seeking long-term disruptive investments. Companies developing technologies that improve outcomes for large numbers of patients can grow exponentially. Our quest is to own those rare firms for long periods while they transform the full value chain of human health.  

Abstract depiction of DNA against a dark blue background.

Radical change, radical possibilities

The future of human health is radically changing. We aim to find and invest in companies that address society’s biggest problems to make healthcare more efficient and accessible and, in turn, generate strong long-term returns for our clients.  

Health Innovation: our philosophy

Investment manager Julia Angeles introduces Health Innovation, reflecting on the exciting opportunities ahead.

Driving transformation

Our objective is to outperform the MSCI ACWI Index by at least 2.5 per cent (net of fees) over rolling five-year periods. We intend to achieve this by investing in companies that are driving the transformation of healthcare, from diagnosis and treatment to efficiency and access.

Our approach is agnostic to sector and benchmark composition. We aim to find and own those few companies that really matter in the theme and hold them in a concentrated portfolio of 25-50 names over the long term, generally for five years or more.   

The performance target is aspirational and is not guaranteed. We don’t use it to compile the portfolio and returns will vary. A single performance target may not be appropriate across all vehicles and jurisdictions. We may not meet our investment objectives if, for example, our growth investment style is out of favour or we misjudge the long-term earnings growth of our holdings.

Different than the average

This is not just another healthcare sector fund. We are not restricted to the MSCI World Health Care Index – our opportunity set is much broader than that. This is a thematic fund. We are experiencing a great convergence of science and technology, and we are seeking the transformative companies at the heart of this. 

That’s why we think we can offer something different. This approach isn’t new to Baillie Gifford. We have been investing in innovation since our inception in 1908, and today close to 15 per cent of our clients’ assets are invested in leading healthcare companies.

Most of the exorbitant costs of healthcare today are associated with care that is not transformative and not personalised. It’s clear that this model is unsustainable.
Marina Record

Meet the managers

Documents

Philosophy and process

Explore our investment process and idea generation as our Health Innovation investors believe it’s time to rethink what the term healthcare means.

Quarterly update

Get the latest investment commentary, portfolio overview, transactions and performance information alongside governance engagement and voting. 

Invest in this strategy

You can invest in this strategy through the following fund(s).

Explore further

Curious to learn more about our products and what we can offer you? Please get in touch.

Strategy portfolio holdings

A list of the top 10 holdings that the representative portfolio invests in.

All figures up to: 31 May 2024

#Holding% of portfolio
1Moderna8.7%
2ALK-Abello5.8%
3argenx5.7%
4Genmab5.6%
5Ambu 5.4%
6Dexcom5.3%
7ShockWave Medical5.1%
8Edwards Lifesciences4.9%
9Alnylam Pharmaceuticals4.4%
10Sartorius Group3.4%

Strategy holdings by region

All figures up to: 31 May 2024

1North America63.00%
2Europe (ex UK)31.40%
3Developed Asia Pacific1.80%
4Emerging Markets1.80%
5UK1.00%
6Cash1.00%
Total 100%

Strategy holdings by region

All figures up to: 31 May 2024

Total: 100%

Please note

The information contained on this page is intended as a guide only and should not be relied upon when making investment decisions. All holdings information is unaudited. Source Baillie Gifford & Co. Please note that totals may not add due to rounding.

Invest in this strategy

You can invest in this strategy through the following fund(s).

Explore further

Curious to learn more about our products and what we can offer you? Please get in touch.

Insights

Key articles, videos and podcasts relating to the strategy:

Filters

Insights

Viewing 18 of 18
  1. Health Innovation Q1 update

    The Health Innovation Team reflects on recent performance, portfolio changes and market developments.
    April 2024
    Video12 minutes
  2. Five years of health innovation

    Investors take note: technology and innovation are revolutionising treatments and patient care.
    March 2024
    Article10 minutes
  3. 왜 지금 성장인가?

    어려운 시기에 발휘되는 파트너십 지배구조의 강점: 급격한 변화 속에서 적응하고 성장할 수 있는 이유에 대해 분석합니다.
    2024년 3월
    Document17분
  4. Five years of the Health Innovation Strategy

    A deep dive into five years of the Health Innovation Strategy and the progress made within healthcare.
    March 2024
    Video43 minutes
  5. Moderna: designing drugs on a computer

    Can scientists meet unmet health needs by writing code to help the body heal itself?
    January 2024
    Article4 minutes
  6. Health Innovation Q4 update

    The Health Innovation Team reflects on recent performance, portfolio changes and market developments.
    January 2024
    Video13 minutes
  7. Why growth, why now?

    Tough times play to the partnership’s strengths: analysing what enables us to adapt and thrive amid rapid change.
    December 2023
    Article17 minutes
  8. Health Innovation Q3 update

    The Health Innovation Team reflects on recent performance, portfolio changes and market developments.
    October 2023
    Video15 minutes
  9. Health Innovation Strategy

    Investment manager, Julia Angeles, discusses the Baillie Gifford Health Innovation Strategy.
    September 2023
    Video3 minutes
  10. Health Innovation Q2 update

    The Health Innovation team reflects on recent performance, portfolio changes, and market developments.
    July 2023
    Video11 minutes
  11. Sustainable investing in the health sector

    The Health Innovation team on ESG, the future of medicine and making a positive global impact.
    February 2023
    DocumentLong read
  12. A dose of innovation

    Your money or your health. Marina Record asks if society is ready to pay for health innovation.
    December 2022
    Article
  13. Disrupting heart disease

    Rose Nguyen on the companies seeking to overcome the scourge of heart disease.
    November 2022
    Podcast24 minutes
  14. Solving the antimicrobial crisis

    If we don’t tackle the AMR crisis now, it could be the world’s biggest killer by 2050.
    November 2022
    Article
  15. Transforming the future of healthcare

    Supporting companies with the potential to transform the field of healthcare and generate attractive returns.
    August 2022
    Video5 minutes
  16. Health Innovation: impact and ESG

    Why the forthcoming Health Innovation Impact Strategy should focus minds.
    January 2022
    Article
  17. Investing in exceptional biotech

    Drugs with fewer side effects, reprogramming the immune system and more from the Health Innovation Team.
    January 2022
    Podcast44 minutes
  18. Health Innovation: it’s time to rethink what the word ‘healthcare’ means

    We are in an era of great convergence. The Health Innovation strategy seeks to support this era of change by looking out for innovative and pioneering companies that have the potential to bring substantial improvements to human health and healthcare systems.
    July 2020
    Video0 minute

Health Innovation Q1 update

The Health Innovation Team reflects on recent performance, portfolio changes and market developments.

  1. Health Innovation Q1 update

    The Health Innovation Team reflects on recent performance, portfolio changes and market developments.
    April 2024
    Video12 minutes
  2. Five years of health innovation

    Investors take note: technology and innovation are revolutionising treatments and patient care.
    March 2024
    Article10 minutes
  3. 왜 지금 성장인가?

    어려운 시기에 발휘되는 파트너십 지배구조의 강점: 급격한 변화 속에서 적응하고 성장할 수 있는 이유에 대해 분석합니다.
    2024년 3월
    Document17분
  4. Five years of the Health Innovation Strategy

    A deep dive into five years of the Health Innovation Strategy and the progress made within healthcare.
    March 2024
    Video43 minutes
  5. Moderna: designing drugs on a computer

    Can scientists meet unmet health needs by writing code to help the body heal itself?
    January 2024
    Article4 minutes
  6. Health Innovation Q4 update

    The Health Innovation Team reflects on recent performance, portfolio changes and market developments.
    January 2024
    Video13 minutes
  7. Why growth, why now?

    Tough times play to the partnership’s strengths: analysing what enables us to adapt and thrive amid rapid change.
    December 2023
    Article17 minutes
  8. Health Innovation Q3 update

    The Health Innovation Team reflects on recent performance, portfolio changes and market developments.
    October 2023
    Video15 minutes
  9. Health Innovation Strategy

    Investment manager, Julia Angeles, discusses the Baillie Gifford Health Innovation Strategy.
    September 2023
    Video3 minutes
  10. Health Innovation Q2 update

    The Health Innovation team reflects on recent performance, portfolio changes, and market developments.
    July 2023
    Video11 minutes
  11. Sustainable investing in the health sector

    The Health Innovation team on ESG, the future of medicine and making a positive global impact.
    February 2023
    DocumentLong read
  12. A dose of innovation

    Your money or your health. Marina Record asks if society is ready to pay for health innovation.
    December 2022
    Article
  13. Disrupting heart disease

    Rose Nguyen on the companies seeking to overcome the scourge of heart disease.
    November 2022
    Podcast24 minutes
  14. Solving the antimicrobial crisis

    If we don’t tackle the AMR crisis now, it could be the world’s biggest killer by 2050.
    November 2022
    Article
  15. Transforming the future of healthcare

    Supporting companies with the potential to transform the field of healthcare and generate attractive returns.
    August 2022
    Video5 minutes
  16. Health Innovation: impact and ESG

    Why the forthcoming Health Innovation Impact Strategy should focus minds.
    January 2022
    Article
  17. Investing in exceptional biotech

    Drugs with fewer side effects, reprogramming the immune system and more from the Health Innovation Team.
    January 2022
    Podcast44 minutes
  18. Health Innovation: it’s time to rethink what the word ‘healthcare’ means

    We are in an era of great convergence. The Health Innovation strategy seeks to support this era of change by looking out for innovative and pioneering companies that have the potential to bring substantial improvements to human health and healthcare systems.
    July 2020
    Video0 minute

Invest in this strategy

You can invest in this strategy through the following fund(s).

Explore further

Curious to learn more about our products and what we can offer you? Please get in touch.

How to invest in this strategy

You can invest in this strategy through the following fund(s).

Explore further

Curious to learn more about our products and what we can offer you? Please get in touch.

Important information

By clicking on South Korea, you have confirmed that you are based in South Korea and that you meet the following requirements.

The information in this area of the website is intended for qualified professional investors and consultants based in South Korea. It is not intended for use by any other persons including members of the general public or investors from other jurisdictions.

Please remember that all investment strategies have the potential for profit and loss and your or your clients’ capital may be at risk.

Baillie Gifford Overseas Limited is wholly owned by Baillie Gifford & Co. Baillie Gifford Overseas Limited provides investment management and advisory services to non-UK clients. Both are authorised and regulated by the Financial Conduct Authority. Baillie Gifford Overseas Limited is licensed with the Financial Services Commission in South Korea as a cross border Discretionary Investment Manager and Non-Discretionary Investment Adviser.

Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 is wholly owned by Baillie Gifford Overseas Limited and holds a Type 1 and a Type 2 licence from the Securities and Futures Commission of Hong Kong to market and distribute Baillie Gifford’s range of collective investment schemes to professional investors in Hong Kong.
Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 can be contacted at Suites 2713-2715, Two International Finance Centre, 8 Finance Street, Central, Hong Kong, Telephone +852 3756 5700.

The information provided does not constitute an offer of or solicitation for purchase or sale of securities or provision of any investment services. Any general enquiries regarding Baillie Gifford should be directed to the relevant individual as noted in the Contact Us section.

The information contained in this website has been compiled with considerable care to ensure its accuracy at the date of publication. However, no representation or warranty, express or implied, is made to its accuracy or completeness. Nothing in this information or elsewhere in this website shall exclude, limit or restrict our duties and liabilities to you under the United Kingdom's Financial Services and Markets Act 2000 or any conduct of business rules which we are bound to comply with.

This website is informative only and the information provided should not be considered as investment advice or a recommendation to buy, sell or hold a particular investment. Read our Legal and regulatory information for further details.